联环药业：子公司美阿沙坦钾片获得药品注册证书

Core Viewpoint - The company announced that its subsidiary, Changle Pharmaceutical, received approval from the National Medical Products Administration for the registration of Mezasartan Potassium Tablets (40mg/80mg), which are used to treat primary hypertension in adults [1] Group 1 - The research and development investment for Mezasartan Potassium Tablets amounted to approximately RMB 10.99 million [1] - As of the announcement date, Changle Pharmaceutical has obtained 10 production licenses for the product [1] - The approval of the drug registration certificate is not expected to have a significant impact on the company's recent operating performance [1]